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Abstract

Pseudomonas aeruginosa is a Gram-negative bacterium commonly found
throughout the environment. It is a significant cause of disease and mortality in
immunodeficient patients such as those suffering from cystic fibrosis (CF). Due to the
emerging antibiotic resistance of P. aeruginosa, it is becoming increasingly more
challenging to treat an infection by traditional means. Further complicating treatment, P.
aeruginosa secretes a protein known as Inhibitor of Vertebrate Lysozyme (PaIVY) that
binds to and inhibits C-type lysozyme, thus preventing the degradation of the bacterium.
A reactive chemical warhead was synthesized from a rhenium(I) tricarbonyl derivative in
order to bind to and irreversibly inhibit PaIVY, thereby allowing endogenous host
lysozyme to effectively degrade drug-resistant P. aeruginosa bacteria. Various
biophysical methods, such as fluorescence spectroscopy, NMR, and mass spectrometry
are utilized in the characterization of the rhenium(I) tricarbonyl derivative and the
binding interaction PaIVY experiences when placed in the presence of the chemical
warhead.
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Chapter One
Background and Significance
Cystic fibrosis (CF) is an autosomal recessive genetic disorder that affects about
70,000 people worldwide with 1,000 new cases annually.1 CF is a disorder of the
exocrine glands that results from a mutation in the cystic fibrosis transmembrane
conductance regulator protein-coding gene (CFTR). These mutations affect sodium and
chloride ion transport at the apical surface level of exocrine gland epithelial cells. In
healthy individuals, a thin, salt containing layer of mucus coats the surface of the
respiratory tract, trapping debris and pathogens that will be swept out by cilia. For
individuals with a mutation in the CFTR protein, the result is too little chloride transport
and too much sodium transport. Due to the excess sodium, water is depleted from the
secretions creating a thick mucus that accumulates in the lungs allowing for bacterial
growth and infection.2
Pseudomonas aeruginosa is an opportunistic bacterium widely found throughout
the environment in soil and water. For healthy individuals an infection would be mild if
established at all. However, for immune compromised individuals, or those suffering
from CF, the infection is responsible for a high rate of morbidity and mortality.3 P.
aeruginosa is one bacterium that finds home in the thick mucus secretions found in the
respiratory tract of patients with CF. The bacterium produces a biofilm which is highly
tolerant towards the host immune system and helps enable the pathogen to be up to 1,000
times more tolerant to antibiotics.4 Further complicating matters, P. aeruginosa secrets a
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protein known as Inhibitor of Vertebrate Lysozyme (PaIVY) from its periplasm. This
protein inhibits C-type lysozyme that would normally compromise the structural integrity
of the bacterial cell wall by catalyzing the hydrolysis of the β-1,4 glycosidic bond
between N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) that are the
disaccharide building blocks of the peptidoglycan polymers in the bacterial cell wall5
(Figure 1). Eradicating P. aeruginosa infection is increasingly more difficult due to its
growing antibiotic resistance and production of PaIVY, producing a need for alternative
treatment methods.

Figure 1. Composition of the bacterial cell wall indicating lysozymes cleavage site; NAG
and NAM are represented by the red and green hexagons, respectively, while peptide
chains are indicated by the blue lines.
One target for inhibiting PaIVY is an exposed loop with H62 at the center that is
involved in the inhibition of lysozyme (Figure 2). When PaIVY interacts with lysozyme
the loop from PaIVY occupies the active site of lysozyme forming hydrogen bonds with
two of the three residues, Aps52 and Glu35, involved in its enzymatic activity.7
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Transition metals yield promising results for binding amino acids which could block this
interaction from occurring.9

Figure 2. Ribbon structure of PaIVY; shown in red is the exposed loop with H62
indicated by a stick structure on the loop.8
Metal complexes have re-emerged as enzyme inhibitors because of their structural
diversity, adjustable ligand exchange kinetics, fine-tuned redox activity, and their distinct
spectroscopic signatures.9 These metal complexes are used in biological systems by
forming coordination bonds to residues at the protein surface or in the active site. A
reactive warhead, or covalent inhibitor, contains a specific group that is designed to react
with a target typically an amino acid side chain that is part of the catalytic activity by
covalent binding. The covalent binding is much stronger than typically non-covalent
interactions such as hydrogen bonds or salt bridges, therefore frequently resulting in an
irreversible interaction.10
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Rhenium cations are increasing in interest due to the potential to be used as a
radiological imaging agent or as a therapeutic radiopharmaceutical similar to technetium.
There is a further interest in the coordination chemistry of rhenium complexes with
biological molecules due to its potential to be used as a bifunctional chelating agent
(BFCA) in drug designs.11 Rhenium(I) tricarbonyl molecules have been identified to bind
to nucleic acids, nucleotides, polypeptides, and amino acids. Of particular interest
Re(CO)3(H2O)3+ has been identified to form complexes with N-acetyl histidine and
histidylhistidine, making it an ideal candidate to design a reactive warhead targeting H62
of PaIVY.11 Furthermore, diamine rhenium tricarbonyl complexes are favored for their
strong luminescence that can be used in characterization.12 Other techniques such as
nuclear magnetic resonance, mass spectrometry, and X-ray crystallography are also often
important in characterization and identification of these types of compounds and for
monitoring complex formation to biomolecules.13, 22, 23
Nuclear magnetic resonance (NMR) has a growing role in the drug discovery
process with the ability to identify binding sites, affinities, and ligand poses at the
individual amino acid level without necessarily solving the structure of the protein-ligand
complex.13 Heteronuclear single quantum coherence (HSQC) is a 2-dimensional NMR
pulse sequence that is frequently used in protein chemistry. Using a 15N-labeled protein,
an HSQC provides a fingerprint of the folded protein by showing a peak for each nonproline amino acid in the backbone due to the variation in chemical environment each
residue experiences. Once each peak is assigned, HSQC can be used to monitor protein
interactions with any unlabeled ligand that is added to the protein solution and afford
residue specific information about chemical changes. Chemical shift perturbation arises
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from changes in the chemical environment the nucleus experiences from conformational
changes induced by a binding event making HSQC a reliable source for identifying if
binding of a reactive warhead occurs and at what amino acid residue(s).14
Other biophysical methods can be utilized to characterize complex formation
including mass spectrometry and fluorescence. There is a wide range of mass
spectrometry techniques that can be used for molecule characterization including matrixassisted laser desorption/ionization (MALDI), liquid chromatography-mass spectrometry
(LC-MS), and electrospray ionization mass spectrometry (ESI-MS). ESI-MS is of
particular interest for characterization of the warhead alone as well in complex with
PaIVY because ESI-MS applications include protein-ligand binding experiments. ESI is a
soft ionization technique that converts solution-phase analytes to gas-phase analytes and
measures the mass-to-charge ratio (m/z).15 ESI-MS begins by introducing the sample to
the ionization source in the mass spectrometer where the solution-phase analytes are
converted to gas phase analytes using electrical energy and obtain a positive or negative
charge. From here they arrive at the detector based on the m/z ratio. Once the ions are
detected the signals are transferred to a computer which displays the information
graphically providing a fingerprint for the compound.16 This information will be used to
verify the identity of the synthesized warhead as well as identify where the warhead is
interacting with PaIVY.
The use of fluorescence in biological sciences for cellular and molecular imaging
has grown rapidly because there is no longer the need for expensive and difficult to
handle radioactive tracers while the detection remains highly sensitive. 17 There are
many different techniques in which fluorescence can be monitored to reveal valuable
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information about a compound such as fluorescence resonance energy transfer (FRET),
fluorescence polarization or steady state fluorescence. Steady state fluorescence is the
most common type of fluorescence in which the sample is illuminated with a continuous
beam of light and the intensity or emission spectrum is recorded.17 Fluorescence studies
can be carried out on many rhenium compounds due to their distinct spectroscopic
signatures depending on the different ligands attached and the solvent used. The distinct
absorption and emission spectra the rhenium compound exhibits are highly useful in
characterization and binding studies. One way fluorescence can be used in binding
studies is by determining the rate of the reaction. Most proteins do not exhibit any
fluorescence of their own, therefore by attaching a fluorescent molecule the rate at which
the two react can be monitored.
Another important technique that can be used in determining where a ligand is
binding to a protein is site-directed mutagenesis using polymerase chain reaction (PCR).
There are two types of site directed mutagenesis, simple or multiple mutations. A simple
mutation method is based on the amplification of double‐stranded DNA from the
template DNA using complementary oligonucleotides, or primers, carrying the mutation
of interest while multiple mutations either obtain the mutation after several rounds of this
process or can obtain them simultaneously in one reaction.18 In a PCR small amounts
DNA are amplified or copied using a thermocycler. There are three steps to a PCR
reaction: denaturation, where the DNA is heated and denatures becoming single-stranded,
annealing where the primers, containing the mutation, bind to flanking regions of the
DNA, and extension where DNA polymerase extends the 3’ end of each primer along the
template strand.19 There are many commercially available kits for site directed
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mutagenesis that make the process simple as well as many useful websites to help design
primers. For PaIVY, it was proposed that the H62 loop was the active site that binds to
and inhibits lysozyme. Mutating this residue will help indicate if the residue is actually
important in lysozyme inhibition as well as help indicate if the warhead is binding to this
site.
To determine if lysozyme is still active in the presence of an inhibitor such as
PaIVY after site-directed mutagenesis or the addition of a reactive warhead a muramidase
assay or a lysozyme activity assay is performed. This commercially available assay
utilizes fluorescently labeled cells that indicate how active lysozyme is due to the
relationship between the fluorescent signal recorded and activity of lysozyme being
proportional.20 The fluorescent signal increases when lysozyme is properly functioning
and lysing the cells. However, because PaIVY inhibits lysozyme the activity of lysozyme
decreases and therefore the fluorescent signal also decreases as the concentration of
PaIVY increases. This assay plays an important role in determining if the addition of the
reactive warhead to PaIVY will eliminate or reduce PaIVY’s inhibition activity against
lysozyme as well as determine if specific residues of PaIVY are necessary in the
inhibition of lysozyme.
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Chapter Two
Protein Purification and Mutagenesis
To begin research on the interactions between a reactive warhead and PaIVY
purified protein must be available for use. Pseudomonas aeruginosa Inhibitor of
Vertebrate Lysozyme (PaIVY) was purified following a protocol developed by Aaron
Schultz, a previous graduate student, located in appendix two with some modifications.
The original plasmid, PA3902, was purchased from DNASU in a pSpeedET vector with a
six residue His tag containing a TEV cleavage site located at the beginning of the protein
sequence. The plasmid has kanamycin antibiotic resistance.
Following the protocol originally created by Aaron Schultz, the plasmid was
transformed into BL21DE3PLysS single shot cells and onto kanamycin LB agar plates
and left to grow overnight at 37°C. The following day, the transformed cells were used
for an overnight culture. Typically for a 2 L prep, two 100 mL small inoculum flasks
were prepared using LB media or M9 minimal media and left at 37°C overnight. The
following day 50 mL from each flask would be transferred to 1 L flasks containing the
respective media and left to grow to an OD600 of 0.6 at 37°C. Once the correct OD was
reached the cells were induced using L-arabinose and left overnight at 37°C. The next
day the cells were spun into a pellet, lysed using a French Press, and centrifuged again
separating the crude lysate from the cell fragments.
Subsequently the purification process consisted of an immobilized metal affinity
chromatography (IMAC) His1 (Figure 3), followed by dialysis and TEV cleavage. The
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His1 fraction is dialyzed for three hours to remove excess imidazole before TEV is added
and then left overnight at room temperature. The following day a His2 (Figure 4) is
performed and the peak fraction is concentrated down to approximately 2 mL. From this
point the concentrated His2 peak is loaded on the size exclusion chromatography (SEC)
column which will separate the protein by size (Figure 5) and therefore allowing for a
pure sample of the protein of interest. In the outlined protocol the SEC is typically run in
SEC buffer which consists of 20 mM monobasic potassium phosphate, 20 mM dibasic
potassium phosphate and 200 mM potassium chloride at pH 8.0, however a modification
using a new buffer from what Aaron previously used was adapted in order to save time
on buffer exchange. The new buffer used to run SEC is 20 mM sodium phosphate buffer
pH 6.0 or in sterile 18W water. Once the SEC was completed the peak at the appropriate
place corresponding to the correct molecular size was collected and concentrated to the
desired concentration. The concentration of the protein is dictated by the future
experiments it will be used for. A typical two-liter preparation PaIVY yielded
approximately 1.5 mL at 1.2 mM. After this the protein was aliquoted into smaller
amounts, typically 500uL to be used for future experiments or frozen in the -80°C for
later use.
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Figure 3. His1 chromatogram of wild type PaIVY purification showing good separation
between the 280 nm (green) and 255 nm (teal) wavelength in the elution phase indicating
viable protein requiring further purification.

Figure 4. His2 chromatogram of wild type PaIVY purification. After His tag has been
removed showing good separation between the 280 nm (green) and 255 nm (teal)
wavelength.
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Figure 5. SEC chromatogram of wild type PaIVY purification. A symmetrical peak at
the correct molecular weight for the protein of interest indicating pure PaIVY.
Performing site-directed mutagenesis on a protein has the potential to alter the
purification protocol due to the potential loss or difference caused in the stabilization of
the protein. H62 is the proposed active site of PaIVY making it an important target for
site-directed mutagenesis. When the histidine residue is mutated valuable information can
be gathered about the significance this residue plays in inhibition of lysozyme as well as
its significance in binding to the reactive warhead. Initially site-directed mutagenesis was
only intended to be performed for H62, however as data was collected via NMR studies
about the warhead binding, further mutagenesis was performed on H20.
Site directed mutagenesis was performed on PaIVY to further understand H62’s
role in inhibition of lysozyme as well as its importance in warhead reactions. Previously,
primers were originally designed by Aaron Schultz to mutate H62 to alanine, although he
was never able to successfully obtain H62A before leaving. Site-directed mutagenesis
was performed successfully by laboratory technician Sarah Waldron using these primers
and following pfuUltra High-Fidelity DNA polymerase AD protocol.6 Once the correct
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mutation was successfully incorporated the DNA was transformed to DH5a cell line and
mini-prepped to readily usable plasmid to be used in future experiments. When purifying
H62A mutant protein the protocol was followed with the SEC buffer modification. H62A
mutant typically did not express as well as wild-type PaIVY, usually only 0.5 mL at 1.2
mM was collected per two-liter prep.
It has been proposed that H62 is the active site of PaIVY in its inhibition of
lysozyme and the proposed location that the warhead will bind, therefore mutating this
residue should reduce or eliminate lysozyme inhibition, as well as no longer bind to the
warhead. However, muramidase assays showed that H62A mutant still inhibits lysozyme
and NMR studies showed that there is still chemical shift perturbation when the warhead
is reacted with H62A mutant. The chemical shifts seen on the HSQC spectra for both
wild-type PaIVY and the H62A mutant point to H20 as the possible alternative binding
site. To further investigate this, new primers were designed to mutate H20.
Primers were designed using PrimerX. Once on the website the original plasmid
sequence from DNASU of PaIVY was uploaded. Step two was left blank and for step
three the primer design protocol drop-down menu was changed to QuickChange sitedirected mutagenesis kit by Stratagene. Initially the goal was to mutate His20 to alanine
like H62 was, however there were no primers generated for alanine so various other
amino acids were tried. On the next page, the plasmid sequence was copied to the box
and the mutation was manually changed from CAT coding for histidine to GAT coding
for aspartic acid. Once PrimerX generated primers for H20D these primers were copied
and pasted into Oligo Calc to identify any hairpins, annealing points, and selfcomplementary. Aspartic acid was chosen because it only required one nucleotide to be
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changed and the primers designed contained one annealing site whereas many others had
multiple annealing sites as well as a hairpin formation. Next the forward and reverse
primers were ordered from idtDNA.
The primers were initially diluted to 100uM. Then following pfuUltra HighFidelity DNA polymerase AD protocol, PCR was performed using wild type PaIVY as
the template DNA for one PCR reaction. In a separate PCR reaction tube H62A mutant
plasmid was used as the template DNA to get the H20D/H62A double mutant PaIVY
with no other histidine’s in the sequence. Following a DNA gel was run on both sets of
mutants and a band was seen indicating that the PCR worked. Next the DNA was
transformed using DH5a cells and left to grow overnight on an LB agar kanamycin plate.
Colonies from each plate were mini prepped to obtain the plasmid. E.Z.N.A Plasmid
DNA Mini Kit II was used. The plasmid was eluted into 40uL sterile deionized water at
219ng/uL and 150ng/uL for H20D and H20D/H62A respectively. The plasmid was then
set for sequencing using Genewiz DNA Sequencing Services.
Protein purification was carried out following wild type PaIVY protocol to ensure
the same protocol and buffers would work for the mutants. The original protocol worked
for both mutants except during the dialysis and TEV cleavage. In the His2 spectrum there
is a peak of uncleaved protein in the elution meaning not all of the His tag was cut off
from the protein during the dialysis and TEV cleavage. The peak was not significantly
large enough to do a second dialysis and TEV cleavage, but there likely needs to be a
higher concentration of TEV added to the dialysis in order to cleave all of the protein. At
the size exclusion chromatography (SEC) step, both mutants were run in the SEC buffer
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initially because they were unlabeled and would not be used for NMR studies. Later the
same modification of performing the SEC in other buffers was utilized for NMR studies.

1 2

3 4. 5 6 7
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9 10 11 12 13

1. Ladder
2. H20D His1
3. H20D His2
4. H20D SEC
5. H20D/H62A His1
6. H20D/H62A His2
7. H20D/H62A SEC (Fraction 14)
8. H20D/H62A SEC (Fractions 16-18)
9. H20D/H62A SEC (Fractions 19-20)
10. H62A 0.43mM
11. H62A + [Re(CO)3(H2O)3]Cl+ (1)
12. H62A + [Re(CO)3(Phen)H2O]Cl+ (3)
13. Ladder

Figure 6. SDS-PAGE gel of H20D PaIVY and H20D/H62A PaVIY
When sequencing arrived back, it was confirmed that the correct mutation was
found on both. Moving forward, the next step was to purify the mutant proteins using 15N
labeled ammonium chloride in M9 minimal media to use for NMR studies. When
preparing samples for NMR, the only purification difference is that the SEC is run in 20
mM sodium phosphate buffer at pH 6.0. to eliminate the need for buffer exchange later.
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Chapter Three
Designing a Warhead and NMR Spectrometry
Due to its ability to bind to amino acids and specifically its ability to bind Nacetyl histidine and histidylhistidine residues such as the histidine-62 (H62) residue of
PaIVY, the original warhead of focus is a rhenium(I) tricarbonyl complex.
Re(CO)3(H2O)3+ (1) was found to bind to His15 of Hen Egg White Lysozyme (HEWL)8
sparking the idea that it would also be an ideal candidate for a reactive warhead targeting
the exposed H62 loop on PaIVY. To begin testing this hypothesis [Re(CO)3(H2O)3]Br+
(1) was synthesized following the published protocol by Lazarova et al.24 in which
Re(CO)5Br+ or Re(CO)5Cl+ was refluxed for several hours with water to produce
[Re(CO)3(H2O)3]Br+ (1) (Figure 7). After the reaction was refluxed to completion, the
product containing solution was transferred to a 50 mL falcon tube and placed in the 80°C freezer overnight. The following day the frozen solution was lyophilized for 24
hours. The product was a tan/white, flakey solid that is easily soluble in water. Once
[Re(CO)3(H2O)3]Br+ (1) was synthesized, a stock solution in water was made at 100 mM
concentration which would be used in following experiments.
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Figure 7. Structure of Re(CO)3(H2O)3+ (1)
To test the viability of this warhead (1), the stock solution of [Re(CO)3(H2O)3]Br+
(1)was combined with 15N labeled PaIVY, purified by adapting a prior student’s, Aaron
Schultz’s, protocol as described in appendix two, to monitor any binding interactions
using an HSQC program on the Bruker 400 MHz NMR located at Kennesaw State
University. The NMR spectra were all processed using NMRPipe and analyzed with
SPARKY.
Several experiments were performed initially to gauge how much of the warhead
(1) would be necessary and at what time point the reaction between [Re(CO)3(H2O)3]Br+
(1) and PaIVY was completed. To test this, 1.25 mM 15N PaIVY was reacted with the
warhead (1) at 5x molar equivalents and monitored at time zero, 24 hours, 72 hours, and
seven days incubation time. At a high concentration of 15N PaIVY and 5x excess warhead
(1) with a short incubation time of 24 hours, it was found that many of the previously
visualized amino acids peaks from the reference 15N HSQC of PaIVY containing no
warhead were no longer present after reacting with [Re(CO)3(H2O)3]Br+ (1) (Figure 8).
This result demonstrated some of the limitations of using NMR. One drawback of using
NMR is that high molecular weight species are not visible. However, the addition of just
the small molecule such as the warhead (1) should not cause the molecular weight to
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become too large and no longer visible. From this is was speculated that multiple protein
molecules were interacting with one warhead (1) and creating a dimer or trimer-like
complex that would have a much higher apparent molecular weight with broader
lineshapes that would make the protein difficult to observe by solution NMR.

Figure 8. Reference HSQC of 15N PaIVY at 1.23 mM with no warhead(red) overlaid
with few residual peaks from 1.25 mM 15N PaIVY reacted with five equivalents of
[Re(CO)3(H2O)3]Br+ (1) (blue) both in 20 mM sodium phosphate buffer pH 7.4. Due to
the disappearance of the peaks, i.e. linebroadening, it is proposed that there is likely high
molecular weight species being formed that limit NMR visibility of the compound.
To further investigate this phenomenon, a size exclusion chromatography (SEC)
experiment that separates species based on their molecular weight was applied to the
NMR sample (Figure 9). Interestingly the SEC showed three to four new peaks eluting
between 50 and 62 mL whereas purified monomer IVY elutes at 69 to 72 mL. These
additional peaks indicate multiple species of higher molecular weight which
corresponded to dimers, trimers, and other oligomers of PaIVY that are formed in the
presence of the warhead (1). This was then confirmed with an SDS-PAGE protein gel
(Figure 10). In the last four lanes it can be seen that there are two additional bands at
higher molecular weight confirming oligomerization. The SEC also showed that at this
17

high concentration the formation of the trimer-like complex and dimer was favored over
the monomer which can be seen by the significantly higher peak on the SEC for the
higher molecular weight species.

Peaks 1/2

Peak 3

Figure 9. Size exclusion chromatography (SEC) spectrum of 1.25 mM PaIVY reacted
with five equivalents of [Re(CO)3(H2O)3]Br+ (1) in 20 mM sodium phosphate buffer at
pH 7.4. Peaks labeled corresponding to fractions collected and run on SDS-page gel in
Figure 10. Peaks 1/2 correspond to oligomers of PaIVY. Peak 3 corresponds to the
monomer peak of PaIVY.
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1. Ladder
2. PaIVY heated
3. Peak 1/2 heated
4. Peak 3 heated
5. Peak 1/2 heated, BME
6. Peak 3 heated, BME
7. PaIVY heated, BME
8. PaIVY unheated
9. Peak 1/2 unheated
10. Peak 3 unheated
11. Peak 1/2 unheated, BME
12. All peaks unheated, BME

9 10 11 12

Figure 10. SDS-PAGE protein gel using various conditions to show PaIVY is present in
higher molecular weights than usual indicating one [Re(CO)3(H2O)3]Br+ (1) is
coordinating to multiple PaIVY molecules. Boiling causes the oligomers to dissociate
while they remained in the unheated samples. (Peaks from Figure 9 SEC).
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Due to the formation of these higher molecular weight species the warhead was
redesigned to stop the coordination of multiple PaIVY molecules to the rhenium
warhead. A rhenium tricarbonyl complex was still the primary focus for a warhead but
there needed to only be one site for the complex to coordinate to PaIVYs histidine
residue, i.e. only one easily exchangeable water ligand, in order to prevent the formation
of dimers and trimers. From this criterion the ideal warhead contains rhenium(I) at the
center coordinating to three carbonyls and a bidentate ligand such as phenanthroline or
bipyridine that leaves one rhenium coordination site free and able to coordinate to H62 of
PaIVY. Re(CO)3(Phen)+ (2-4) became the focus of the new warhead design. Figure 11
shows a representation of how the warhead (2-4) is intended to coordinate to H62 of
PaIVY.
O
O
N
H 3N
N
O

N
Re
N

O
O

Figure 11. Schematic of Re(CO)3(Phen)+ (2-4), shown in black, coordinating to a
histidine, shown in blue.
Re(CO)3(Phen)X+ was synthesized in two ways. Initially, [Re(CO)3(H2O)3]X+ (1)
had already been synthesized, so it was utilized in the synthesis for the newly designed
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warhead (2,3). Previously synthesized [Re(CO)3(H2O)3]X+ (1) was mixed with 1,10
phenanthroline in a 1:1.1 molar ratio in a round bottom flask containing acetone at room
temperature with stirring to form [Re(CO)3(Phen)H2O]Br+ (2). The solution immediately
turned bright yellow supporting product formation. Next, the mixture was moved to a 50
mL falcon tube and left open to evaporate the acetone over the next few days until a fine
yellow powder was left. Another variation of this same warhead is
[Re(CO)3(Phen)H2O]Cl+ (3) in which Re(CO)5Cl is the starting material instead of
Re(CO)5Br. The reaction is carried out in the same way with a difference being the
halogen ion that remains in solution as well as the option to carry it out in a H2O solution
containing purified protein in the second step.
A more efficient protocol published by Chakraborty et al.12 was discovered which
required a one-step process. Since this protocol was one-step the remaining H2O on the
warhead from the previous protocol was replaced with a Cl because the starting material
is Re(CO)5Cl. The H2O from the previous protocol and the Cl from the new protocol
would be replaced when reacted with PaIVY. A comparison of all the warheads
synthesized and their structural differences can be seen in Figure 12 and Figure 13. The
synthesis required one molar equivalent of Re(CO)5Cl to be mixed with 1,10phenanthroline in chloroform and methanol and then refluxed for 24 hours to create
Re(CO)3(Phen)Cl+ (4). The product was then vacuum filtered and left to dry for several
days leaving a fine yellow powder.
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Figure 12. Structures for each warhead (1-4).
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Figure 13. Reaction schemes of each warhead used. 2 and 3 made in the two-step process
involving Re(CO)3(H2O)3+ differing only in the halogen ion present. Warhead 4 made in
the one-step process.
Once both identities were confirmed, the focus of the warhead became
Re(CO)3(Phen)Cl+ (4) because it was easily produced by the one-step synthesis. To test
the viability of the new warhead (4) design, several 15N HSQC NMR experiments were
performed in order to find the ideal incubation time of the reaction to reach completion as
well as how much excess of the warhead (4) would be necessary. 1.06 mM purified 15N
PaIVY was reacted with one, three, and five molar equivalents of warhead (4). It was
monitored using the 400 MHz NMR located at KSU at time zero, 24 hours, 72 hours,
seven days, and 10 days. Each of the different concentrations showed no changes at time
zero, little to no changes at 24 hours (Figure 14), and many slight changes after three
days (Figure 15). The 15N HSQC showed some chemical shift perturbation, but it was
not as significant as expected. It was speculated that due to the low solubility of
phenanthroline in water that not enough of the warhead (4) was in solution to show a
significant chemical change on the NMR. Unfortunately, there is little to change about
the buffer solution containing PaIVY in order to improve solubility of the warhead (4)
due to the protein’s need to be in an aqueous environment or risk denaturation. In an
attempt to help improve the solubility of the warhead (4), the pH of the phosphate buffer
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CO

CO

was reduced from 7.4 to 6. Unfortunately, this did not significantly change the solubility
of the warhead (4), so a new technique needed to be adapted in order to achieve the
complex formation between the warhead (4) and PaIVY.

Figure 14. Overlay of the reference 15N HSQC at 1.23 mM (red) and 1.06 mM PaIVY
reacted with three equivalents of [Re(CO)3(Phen)H2O]Br+ (2)after 24 hours incubation
(blue). No chemical shift perturbations noted.
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a.

b.

Figure 15. a.) Overlay of the reference 15N HSQC at 1.23 mM (red) and 1.06 mM PaIVY
reacted with three equivalents of [Re(CO)3(Phen)H2O]Br+ (2) after three days incubation
(blue). Labels in yellow indicate some of the notable chemical shift perturbations. b.)
Zoomed in image from Figure 11 to show the slight chemical shifts noted in yellow.
Due to the solubility issue, it was later decided to do the reaction in two parts.
First allow a two times excess of [Re(CO)3(H2O)3]X+ (1) to react with purified PaIVY at
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a low concentration, about 0.5 mM, for two days and then add an excess of
phenanthroline into the reaction tube to react for an additional two days. The solution
began turning yellow after the first 24 hours and increased in intensity by the 48 hours
reacting at room temperature. The color after 48 hours can be seen in Figure 16. The
reaction was then loaded on the SEC column and the monomer peak was collected
(Figure 17), concentrated to 0.5 mM and subsequently an HSQC NMR was performed
using the 600 MHz NMR located at KSU. It can be seen that doing this reaction at a
lower concentration than previously favored the formation of the monomer peak rather
than a trimer or dimer (Figure 18). The HSQC spectra showed promising results of
chemical shift perturbation however, many of the peaks were split indicating that not all
of the PaIVY was in complex with the warhead (3). Another interesting discovery was
that majority of the amino acid residues that experienced a shift were not located near
H62 as expected but rather near H20 (Figures 18 and 19).

Figure 16. Reaction tubes after 1,10-phenanthroline was added to PaIVY reacted with
[Re(CO)3(H2O)3]X+ (1) indicating the formation of the warhead (3) due to the yellow
color.
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Figure 17. Size exclusion chromatography (SEC) of [Re(CO)3(Phen)(H2O)]Cl+ (3)
reacted with PaIVY

Figure 18. 15N HSQC spectra of monomer peak from SEC of [Re(CO)3(Phen)(H2O)]Cl+
(3) reacted with PaIVY at 0.3 mM in blue. Reference HSQC in red at 1.06 mM PaIVY
after 72 Hr.
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Figure 19. Surface crystal structure of PaIVY.8 In green are the amino acid residues with
the most chemical shift perturbation after reacting with the warhead (3). The rest of the
amino acid residues are in red. H20 shown in blue. H62 is shown in yellow.
To investigate further that H62 is not the warhead (3) binding site site-directed
mutagenesis was performed and more NMR studies were done. Using the same technique
of reacting purified 15N PaIVY with [Re(CO)3(H2O)3]X+ (1) then adding 1,10phenanthroline and SEC purifying the sample, 15N HSQC was performed at 600 MHz. As
it was suspected, the H62A mutant PaIVY still had chemical shift perturbation when it
was reacted with the warhead (3) (Figure 20). This indicated that H62 was not the
binding site for the warhead (3). Additionally, an SDS-Page gel was run that indicated the
H62A mutant was also forming dimer/trimers with PaIVY indicating the warhead (3) was
reacting with H62A (Figure 21). In order to uncover if the warhead (3) was binding to
H20 instead site-directed mutagenesis was performed for a second time.
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a.

b.

Figure 20. a.) H62A reference in red at 200uM in a 300 mm tube overlaid with H62A
reacted with [Re(CO)3(Phen)(H2O)]Cl+ (3) in blue at 0.5 mM in a 5 mm tube. This
indicated the warhead (3) is still binding to PaIVY without H62 present. b.) Zoomed in
view to see chemical shift perturbation.
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1. Ladder
2. PaIVY 0.5mM
3. PaIVY w/ Re(CO)3(H2O)3 0.38mM
4. PaIVY monomer SEC peak 0.38mM
5. PaIVY dimer SEC peak 0.38mM
6. PaIVY trimer SEC peak 0.38mM
7. PaIVY w/ Re(CO)3(H2O)3 0.35mM
8. PaIVY w/ Re(CO)3(Phen)Cl+ 0.35mM
9. PaIVY monomer SEC peak 0.35mM
10. H62A PaIVY w/ Re(CO)3(H2O)3 0.4mM
11. H62A PaIVY w/ Re(CO)3(Phen)Cl+
0.4mM
12. H62A PaIVY monomer SEC peak
10 11 12 0.4mM

Figure 21. SDS-PAGE gel image of wild type PaIVY and H62A mutant at different
stages of soaking with the warhead (1,3).
The next step in figuring out if the warhead (3) was binding to H20 instead was
site-directed mutagenesis to H20D. A single mutant and a double mutant removing both
histidine residues in PaIVY was made. Next both of these mutants were reacted with the
warhead (3) using the same technique and subject to NMR using the 600 MHz located at
KSU. The HSQC spectra of the H20D and H20D/H62A mutants do not contain amino
acid labels because the spectra were altered when the mutations were made requiring the
need for three-dimensional NMR analysis to locate the residues and apply appropriate
labeling that was not done. The HSQC spectra of the H20D mutant showed little to no
chemical shift perturbation but rather broadening. This is most clearly noticed on residues
G38 and S39 (Figure 22). These two residues were also affected when wild type PaIVY
as well as H62A mutant was reacted with the warhead (3). This indicates that
[Re(CO)3(Phen)(H2O)]Cl+ (3) is still binding to H20D mutant PaIVY but not as widely as
previously. One explanation for this is a conformational change may be occurring when
the warhead (3) binds. To further investigate this the H20D/H62A double mutant was
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also subject to a reaction with the warhead (3) and an HSQC was performed. This NMR
spectra showed no chemical shift perturbation indicating that the warhead (3) was not
binding to any other residue on PaIVY (Figure 23). This confirms that there is likely a
conformational change happening when the warhead (3) binds that involves both the H20
and H62 residues.
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a.

b.

Figure 22. a.) Reference HSQC of H20D at 1.2 mM in red overlaid with H20D reacted
with the warhead (3) at 0.38 mM in blue. b.) Zoomed in image.
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a.

b.

Figure 23. a.) Reference HSQC of H20D/H62A double mutant at 1.4 mM in red overlaid
with H20D/H62A reacted with the warhead (3) at 0.48 mM in blue. b.) Zoomed in image.
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Chapter Four
Muramidase Assay of Wild Type and Mutant PaIVY with and without the
Warhead
A muramidase assay is a lysozyme activity assay in which the ability of lysozyme
to lyse cells is monitored using fluorescence when in the presence of PaIVY. In the assay
lysozyme activity is measured on Micrococcus lysodeikticus cell walls which are
fluorescently labeled to allow for quantification of the cells being lysed. The cells are
labeled in such a way that the fluorescence is suppressed when the cells are lysed. The
catalytic activity of lysozyme combats this quenching causing an increase in the
fluorescent signal detected when it is properly functioning. The fluorescent signal
detected is proportional to the activity of lysozyme20 making this assay extremely useful
in determining if certain residues in the protein sequence are important or necessary for
the inhibition of lysozyme as well as indicate if the addition of a reactive warhead (3) will
prevent PaIVY from inhibiting lysozyme. In this assay Hen Egg White Lysozyme
(HEWL) is used. It is expected that when wild type PaIVY is placed in the presence of
lysozyme the cells fluorescence signal will decrease due to PaIVY’s ability to inhibit
lysozyme and therefore prevent lysing of the cells. This can be seen in Figure 24.
Each muramidase assay was performed using Enzcheck Lysozyme Assay Kit (E22013).20 The DQ cells were prepared following this protocol, however the lysozyme
provided in the kit was not used but rather HEWL purchased from Hampton Research
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and was prepared by making a 5 mM stock solution. Each assay was prepared using
Corning 96 well black polystyrene plates with a clear bottom. For each muramidase
performed 25uL of HEWL was used in each well, a varying amount of PaIVY was used
based on the original concentration of the protein, a varying amount 1X reaction buffer to
bring the volume of PaIVY and 1X reaction buffer to 25uL total and lastly each well
contained 50uL of fluorescently labeled DQ cells. The total volume used in each well
was 100uL. The exact amounts used in each well for each reaction can be seen in Tables
1 and 2. DQ cells were always added last to ensure the each well reaction started at
approximately the same time. Once each well had the proper amount of each component,
the plate was placed in darkness and left for 30 minutes until the fluorescent signal was
measured using the Synergy H1 fluorescent plate reader. The plate reader was set to an
excitation of 485 nm and emission scan at 530 nm and the background fluorescence was
subtracted using the blank.

Concentration of Wild Type PaIVY Vs. Percent Lysis
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Figure 24. Muramidase assay of wild type PaIVY at various concentrations in the
presence of 100 nM hen egg white lysozyme (HEWL).
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The proposed active site of PaIVY’s inhibition of lysozyme is the exposed H62
loop, therefore it was hypothesized that when H62 is mutated to H62A there would no
longer be a decrease in the fluorescence signal in the assay because lysozyme would be
free to effectively lyse the cells. Once the H62 residue of PaIVY was correctly mutated to
alanine, a muramidase assay using the mutated protein was performed following Table 1
concentrations. Interestingly, the H62A mutant behaved almost identical to wild type
IVY when in the presence of lysozyme. This is indicated by the fluorescent signal
decreasing as the concentration of PaIVY increased (Figure 25). The decreasing
fluorescence recorded with increasing concentrations of PaIVY in combination with BLI
data collected by another graduate student Amani Gaddy, indicated the H62A mutant still
binds lysozyme only slightly weaker than wild type IVY disproved the hypothesis that
H62 is responsible solely for the inhibition of lysozyme.

Concentration of H62A Mutant PaIVY Vs. Percent Lysis
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Figure 25. Muramidase assay of H62A mutant PaIVY at various concentrations in the
presence of 100 nM hen egg white lysozyme (HEWL).
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Table 1. Concentrations of each IVY used in the free protein muramidase assays in
Figures 24, 25, 28, and 29.

H20D

100 nM
HEWL

H20D/
H62A

100 nM
HEWL

Wild
Type
PaIVY

100 nM
HEWL

H62A

100 nM
HEWL

100
uM
IVY
4.8 uL
IVY
20.2
uL 1x
50 uL
DQ
25 uL
HEWL

30 uM
IVY

1 uM
IVY

300
nM
IVY
1.4 uL 10 uL
3 uL
IVY
IVY
IVY
23.6
15 uL
22 uL
uL 1x 1x
1x
50 uL 50 uL
50 uL
DQ
DQ
DQ
25 uL 25
25 uL
HEWL HEWL HEWL

10 nM
IVY

3 nM
IVY

0 IVY

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

25 uL
HEWL
25 uL
1x
50 uL
DQ

4.2 uL
IVY
20.8
uL 1x
50 uL
DQ
25 uL
HEWL

2.3 uL
IVY
22.7
uL 1x
50 uL
DQ
25 uL
HEWL

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

25 uL
HEWL
25 uL
1x
50 uL
DQ

Blank

9.5
uL
2.1
mM
IVY
40.5
uL 1x
50 uL
DQ
5.8 uL 1.8 uL 10 uL
3 uL
10 uL
3 uL
25 uL
11.8
IVY
IVY
IVY
IVY
IVY
IVY
HEWL uL
19.2
23.2
15 uL
22 uL 15 uL
22 uL 25 uL
1.7
uL 1x
uL 1x 1x
1x
1x
1x
1x
mM
50 uL
50 uL 50 uL
50 uL 50 uL
50 uL 50 uL
IVY
DQ
DQ
DQ
DQ
DQ
DQ
DQ
38.2
25 uL
25 uL 25 uL
25 uL 25 uL
25 uL
uL 1x
HEWL HEWL HEWL HEWL HEWL HEWL
50 uL
DQ
10.5
3.2 uL 10 uL
3 uL
10 uL
3 uL
25 uL
21 uL
uL
IVY
IVY
IVY
IVY
IVY
HEWL 0.95
IVY
21.8
15 uL
22 uL 15 uL
22 uL 25 uL
mM
14.5
uL 1x 1x
1x
1x
1x
1x
IVY
uL 1x
50 uL 50 uL
50 uL 50 uL
50 uL 50 uL
29uL
50 uL
DQ
DQ
DQ
DQ
DQ
DQ
1x
DQ
25 uL 25 uL
25 uL 25 uL
25 uL
50 uL
25 uL
HEWL HEWL HEWL HEWL HEWL
DQ
HEWL
10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL
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3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

8.5
uL
2.36
mM
IVY
41.5
uL 1x
50 uL
DQ

Table 2. Concentrations of each IVY reacted with the warhead (3) used in muramidase
assays for Figures 26, 27, 30, and 31.
100
uM
IVY

30 uM
IVY

1 uM
IVY

300
nM
IVY

10 nM
IVY

3 nM
IVY

0 IVY

Blank

H20D

100
12.8
nM
uL
HEWL IVY
22.2
uL 1x
50 uL
DQ
25 uL
HEWL

3.8 uL
IVY
21.2
uL 1x
50 uL
DQ
25 uL
HEWL

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

25 uL
HEWL
25 uL
1x
50 uL
DQ

25.6
uL
0.78
mM
IVY
24.4
uL 1x
50 uL
DQ

H20D/
H62A

100
10 uL
nM
IVY
HEWL 15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

25 uL
HEWL
25 uL
1x
50 uL
DQ

20 uL
1
mM
IVY
30 uL
1x
50 uL
DQ

WildType
PaIVY

100
25 uL
nM
IVY
HEWL 0 uL
1x
50 uL
DQ
25 uL
HEWL

7.5 uL
IVY
17.5
uL 1x
50 uL
DQ
25 uL
HEWL

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

25 uL
HEWL
25 uL
1x
50 uL
DQ

50 uL
0.4
mM
IVY
0 uL
1x
50 uL
DQ

H62A

100
8.3 uL
nM
IVY
HEWL 16.7
uL 1x
50 uL
DQ
25 uL
HEWL

2.5 uL
IVY
22.5
uL 1x
50 uL
DQ
25 uL
HEWL

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

10 uL
IVY
15 uL
1x
50 uL
DQ
25 uL
HEWL

3 uL
IVY
22 uL
1x
50 uL
DQ
25 uL
HEWL

25 uL
HEWL
25 uL
1x
50 uL
DQ

16.6
uL
1.2
mM
IVY
33.4
uL 1x
50 uL
DQ

Additionally, it was hypothesized that the addition of the warhead (3) to PaIVY
would block the H62 residue from being able to interact with lysozyme and thus allowing
lysozyme to effectively lyse the cells. Muramidase was performed using warhead (3)
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reacted PaIVY samples reacted using the same technique as previously described for the
NMR experiments of reacting purified PaIVY with [Re(CO)3(H2O)3]X+ (1) then adding
phenanthroline and SEC purifying the sample. Curiously, there was not a significant
difference between the free protein in the presence of HEWL as there was with the
warhead (3) reacted protein (Figure 26). Similarly, the H62A mutant showed no
significant difference between the free protein and the warhead (3) reacted protein in the
presence HEWL (Figure 27). This indicated for both wild-type PaIVY and H62A mutant
PaIVY that either the warhead (3) was not binding to the correct site for inhibition, or
that there was still too much unreacted protein available to inhibit lysozyme.

Concentration of Wild Type PaIVY Vs. Percent Lysis

Percent Lysis
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Figure 26. Muramidase assay of wild type PaIVY at various concentrations in the
presence of 100 nM hen egg white lysozyme (HEWL) in blue and wild type PaIVY
reacted with an excess of the warhead (3) at various concentrations in the presence of 100
nM HEWL.

39

Concentration of H62A Mutant PaIVY Vs. Percent Lysis
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Figure 27. Muramidase assay of H62A mutant PaIVY at various concentrations in the
presence of 100 nM hen egg white lysozyme (HEWL) in blue and wild type PaIVY
reacted with an excess of the warhead (3) at various concentrations in the presence of 100
nm HEWL.
Based off of the NMR studies done previously, it was indicated that H62 was
likely not the binding site for the warhead (3) but rather H20. Once the H20D and
H20D/H62A mutants were successfully expressed, a muramidase assay was done in order
to see if these mutations alone or the addition of the warhead (3) affected PaIVY’s ability
to inhibit lysozyme. The muramidase assay showed almost identical curves for both the
free H20D and H20D/H62A mutant proteins when in the presence of 100 nM HEWL in
which the fluorescent signal diminished as the concentration of PaIVY increased
(Figures 28 and 29). This indicated that the H20D mutation was not important in the
inhibition of lysozyme and that removing both histidine residues from PaIVY also did not
affect the inhibition of lysozyme making it all the more pertinent that the warhead (3)
blocks the interaction between PaIVY and lysozyme.
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Figure 28. Muramidase assay of H20D mutant PaIVY at various concentrations in the
presence of 100 nM hen egg white lysozyme (HEWL).
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Figure 29. Muramidase assay of H20D/H62A mutant PaIVY at various concentrations in
the presence of 100 nM hen egg white lysozyme (HEWL).
H20D and H20D/H62A PaIVY mutants were reacted with the warhead (3) using
the same technique as previously described for other experiments and a muramidase
assay was performed. For both the H20D and H20D/H62A mutant proteins reacted with
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the warhead (3), the muramidase assay showed no inhibition. The curve of the warhead
(3) reacted proteins followed along in a similar fashion as that of the free protein
(Figures 30 and 31). It is to be noted that at a concentration of 0.3uM PaIVY for wild
type and each mutant protein the warhead (3) reacted proteins exhibited a higher percent
lysis. This could indicate that the warhead (3) is making the reaction slower between
PaIVY and lysozyme, but the interaction is not strong enough to fully prevent PaIVY
from inhibiting lysozyme. When the warhead (3) reacted PaIVY is SEC purified the
monomer peak is collected, however because there is not a large discrepancy in
molecular weight of that of free PaIVY and warhead (3) attached PaIVY, the peak
collected could contain both free and reacted protein. Therefore, the similar muramidase
curves could also indicate that there is too much free PaIVY that did not react with the
warhead (3), that is free to interact and inhibit the lysozyme.
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Figure 30. Muramidase assay of H20D mutant PaIVY at various concentrations in the
presence of 100 nM hen egg white lysozyme (HEWL) in blue and wild type PaIVY
reacted with an excess of the warhead (3) at various concentrations in the presence of 100
nm HEWL.
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Figure 31. Muramidase assay of H20D/H62A mutant PaIVY at various concentrations in
the presence of 100 nM hen egg white lysozyme (HEWL) in blue and wild type PaIVY
reacted with an excess of the warhead (3) at various concentrations in the presence of 100
nM HEWL.
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Chapter Five
Fluorescence and Mass Spectrometry Studies
Fluorescence is a useful tool in characterizing and studying fluorescent molecules.
Re(CO)3(Phen)Cl+ (4) is a fluorescent molecule with an excitation at 370 nm and
emission at 605 nm according to Chakraborty et al12. Because three of the four warheads
are fluorescent molecules their fluorescent properties can help indicate whether PaIVY is
reacting with the warhead and help determine the rate of the reaction. When the
fluorescence was initially being investigated warhead 2 was used for these studies.
[Re(CO)3(Phen)H2O]Br+ (2), [Re(CO)3(Phen)H2O]Cl+ (3), and Re(CO)3(Phen)Cl+
(4) each fluoresce, so fluorescence studies were performed to investigate binding to
PaIVY. First using Corning black polystyrene 96-well plates with a clear bottom various
concentrations of [Re(CO)3(Phen)H2O]Br+ (2) and PaIVY solutions were monitored over
the course of one week as well as individual solutions of just PaIVY and
[Re(CO)3(Phen)(H2O)]Br+ (2) for comparison. Using Biotek Synergy H1 an excitation
and emission scan were collected. Initially a fixed excitation was set at 370 nm and
emission at 600 nm based off literature values. It was noted that the wavelength
corresponding to the excitation and emission may fluctuate based on the solution the
compound is in as well as each molecule attached. Later the excitation and emission
values were shifted to 370 nm and 520 nm respectively in order to get a more accurate
reading based on previous scans. Interestingly the warhead (2) complex with PaIVY
surpassed the fluorescent signal of just [Re(CO)3(Phen)H2O]Br+ (2) alone (Figure 32).
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Being that PaIVY does not fluoresce on its own it was proposed that when the warhead
(2) is mixed with PaIVY the binding between the two causes more
[Re(CO)3(Phen)H2O]Br+ (2) to be pulled into solution and therefore the fluorescent
signal increases. This is plausible because the warhead (2) alone is poorly soluble in the
20 mM pH 6 sodium phosphate buffer in which PaIVY is stored. The fluorescence
studies also indicated that the complex formation between the warhead (2) and PaIVY is
time dependent reaching a maximum around day 4 and that the reaction is temperature
dependent as well. When the same experiment was conducted at 4°C versus the usual
25°C, the fluorescence did not increase over time indicating that PaIVY was likely not
binding the warhead (2). The growing fluorescence signal provided a preliminary kinetics
curve following second order kinetics (Figure 33). All of the fluorescent plate studies
were done using [Re(CO)3(Phen)H2O]Br+ (2) because at the time of the experiments the
one-step process to produce Re(CO)3(Phen)Cl+ (4) had not yet been discovered.
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Figure 32. Excitation and emission spectra of free [Re(CO)3(Phen)H2O]Br+ (2) and in
complex with PaIVY at 0.5 mM in 20 mM sodium phosphate buffer at pH 6.
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Figure 33. Intensity vs time for 1 mM and 0.1 mM PaIVY and [Re(CO)3(Phen)H2O]Br+
(2)
Another useful technique to monitor intact proteins and their complexes is
electrospray ionization mass spectroscopy (ESI-MS) because it preserves the protein
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folding and its covalent interactions. The goal of performing ESI-MS was to determine if
the warheads were binding to PaIVY. When doing ESI-MS a raw spectrum is provided
from which the mass and charge can be calculated . If any of the warheads are binding to
PaIVY there will be a shoulder peak on the spectrum that corresponds to the mass of
PaIVY plus any adduct. For ESI-MS each sample was prepared following the
specifications outlined in Table 3 and sent to the University of Georgia’s Proteomics and
Mass Spectrometry facility where the samples were run on the Bruker Esquire 3000 Plus
Ion Trap Mass Spectrometer equipped with an ESI ion source.
Table 3. Electrospray Ionization Mass Spectroscopy (ESI-MS) sample specifications.
Sample #

4

5

6

7

Warhead #

1

2

4

-

Sample

[Re(CO)3(H2O)3]Br+

[Re(CO)3(Phen)(H2O)]Br+

Re(CO)3(Phen)Cl+

PaIVY

Makeup

+PaIVY

+ PaIVY

+ PaIVY

MW
(complex)

14806 Da

14500
14950 Da

14950 Da

Da

In

water

water

water

water

Molarity

100 uM

100 uM

100 uM

100
uM

Volume

50 uL

50 uL

50 uL

50 uL

In order to extract the valuable information from a raw ESI-MS spectrum, two
equations need to be utilized to determine the mass and charge of the peaks present. To
determine the mass, Equation 1 is used where M1 corresponds to the m/z value displayed
on the spectrum for one ion, M2 corresponds to the m/z value displayed on the spectrum
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for the adjacent lower ion, and A corresponds to the mass of the adduct which is typically
a proton but could be a sodium or potassium ion. To determine the charge Equation 2 is
used where z corresponds to the charge present for that peak or cluster of peaks, and all
Equation 121.

other variables follow the same as in
Equation 1.
𝑀𝑊 =

(𝑀% − 𝐴)(𝑀) − 𝐴)
𝑀% − 𝑀)

Equation 2.
𝑧=

𝑀) − 𝐴
𝑀% − 𝑀)

For the free PaIVY ESI-MS the molecular weight calculation is as follows
corresponding to Figure 34. Each calculation was done following this example.

𝑀𝑊 =

(1038 − 1)(968.9 − 1)
(1037)(967.9)
=
= 14.525𝑘𝐷𝑎
1038 − 968.9
69.1
𝑧=

968.9 − 1
= 14
1038 − 968.9

Once the charges are determined for each cluster of peaks based on the raw data,
this information can be used to calculate the average mass and differences in mass
between shoulder peaks in the same charge cluster. This information indicates if there is
an ion exchange happening at a given charge or if the warhead adduct is forming. The
average masses are listed in Table 4 for each of the spectra indicating any adduct
formation with its likely identity. For example, in Figure 34, it can be seen that there is a
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shoulder peak to the right of the +15-charge peak. This peak has a given value of 986.8.
Using this and the charge, the mass is calculated to be 14802 Da with a difference of 270
Da from that of the free protein. This indicates that an adduct is forming on PaIVY
reacted with [Re(CO)3(H2O)3]Br+ (1) at a molecular weight of approximately 270 Da.
This was calculated for each of the peaks seen in Figure 38 with an average adduct mass
of 269 Da. The warhead (1) adduct should have a mass of approximately 304 Da giving a
difference of 35 Da or 35g. The solution that PaIVY was initially purified in was a 20
mM potassium phosphate buffer. It was desalted into water, but due to the discrepancy of
around 39 Da or 39 g/mol found on each of the spectra it is likely that there was still
leftover potassium in the solution that was being exchanged in each of the samples. The
approximately 35 g/mol discrepancy for the mass of the warhead (1) adduct is likely
because there is a potassium ion lost when the warhead (1) is interacting with PaIVY.
Table 4. Average calculated masses from raw ESI-MS data in Figures 34-37.
Warhead

Average

Average

Average

#

Mass of

Mass of any

Mass of the

PaIVY

adduct plus

adduct

Identity of adduct

PaIVY
PaIVY (Figure 37)

-

14532 Da

14571 Da

39 Da

Potassium ion

[Re(CO)3(H2O)3]Br+

1

14532 Da

14801 Da

269 Da

[Re(CO)3(H2O)3]Br+

plus PaIVY (Figure 38)
[Re(CO)3(Phen)H2O]Br+

minus potassium ion
2

14531 Da

14573 Da

42 Da

Potassium ion

4

14531 Da

14570 Da

39 Da

Potassium ion

plus PaIVY (Figure 39)
[Re(CO)3(Phen)]Cl+
plus PaIVY (Figure 40)
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Figure 34. Raw electrospray ionization mass spectrometry data of PaIVY in water at
100uM.

+15
+16

+14

+17
+13

Figure 35. Raw electrospray ionization mass spectrometry data of PaIVY plus
[Re(CO)3(H2O)3]Br+ (1) in water at 100uM.
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Figure 34 shows wild type PaIVY in water at 100uM. The spectrum indicates an
average mass of 14532 Da. The most predominate charge for free PaIVY is +15 indicated
by the largest relative peak followed by +16 and +14 respectively. There is a small peak
for each charge cluster to the right which has an average mass of 14571 Da. It is likely
that this small peak is from potassium ion exchange due to leftover potassium from the
previous buffer. There are no other adducts forming therefore this spectrum is a good
reference to compare the warhead (1) reacted ESI-MS spectra such as in Figure 35.
Figure 35 shows wild type PaIVY reacted with [Re(CO)3(H2O)3]Br+ (1). The
predominate charge is +15 followed by +16 and +14, the same as free PaIVY along with
the average molecular weight remaining consistent. There is a shoulder peak on each of
the charge clusters that is about half the size of the main peak for its respective charge.
This peak is PaIVY plus the adduct with an average mass of 14801 Da. In this case the
peak corresponds to [Re(CO)3(H2O)3]Br+ (1) attached to PaIVY indicating that this
warhead (1) is binding to PaIVY. There is a slight mass discrepancy of 35 Da that is
likely due to the missing potassium ion. Further to the right of this peak there is a slightly
shorter peak belonging to the same charge cluster that has an average mass of 14839 Da
making the adduct approximately 307 Da or 307g/mol which corresponds closely to that
of the molecular weight of the warhead (1).
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+16
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+17

Figure 36. Raw electrospray ionization mass spectrometry data of PaIVY plus
[Re(CO)3(Phen)H2O]Br+ in water at 100uM.

+15
+16

+17

+14

+13

Figure 37. Raw electrospray ionization mass spectrometry data of PaIVY plus
[Re(CO)3(Phen)]Cl+ in water at 100uM.
Figure 36 shows PaIVY reacted with [Re(CO)3(Phen)H2O]Br+ (2) in water at
100uM. Based on the spectrum the average mass of PaIVY is negligibly lower than the
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previous two spectra at 14.531kDa. The predominate charge is 15+ followed closely by
+14 and +16 which differs from the spectrum of the free protein. This spectrum does
have a lot of relatively small shoulder peaks, however none of them are predominant
relative to that of the main peak in the charge cluster or correspond remotely close to the
molecular weight of the warhead (2). This indicates that the warhead (2) is not binding.
The failure for PaIVY to bind to this warhead (2) is likely due to the warhead (2) not
being very soluble in water. Similarly, for Figure 37, it can be concluded that the
warhead (4) is also not binding to PaIVY likely for the same reason due to the lack of any
shoulder peaks that correspond to the molecular weight of the warhead (4). This spectrum
has the same average mass of 14.531kDa, with the most predominate charge being +15
followed by +16 and +14. The spectrum is almost identical to that of the free protein
supporting the fact that the warhead (4) is not bound to PaIVY. There is only one small
shoulder peak on this spectrum similar to that of free PaIVY which corresponds to a
potassium ion exchange.
Based off the ESI-MS data, PaIVY is only readily reacting with
[Re(CO)3(H2O)3]Br+ (1) and not the fluorescent warheads (2-4) containing
phenanthroline. This data verifies that [Re(CO)3(H2O)3]Br+ (1) is reacting with PaIVY
which was indicated by previous NMR experiments. However, this data did not indicate
any dimer/trimer complexes forming, but this could be due to the molecular weight of
those species being outside of the set parameters on the mass spectrometer. This data also
supports the theory that Re(CO)3(Phen)Cl+ (4) and [Re(CO)3(Phen)H2O]Br+ (2) are not
soluble enough in water to react with PaIVY. This information is valuable in that it
helped lead to the decision to react PaIVY with readily water soluble
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[Re(CO)3(H2O)3]Br+ (1) first and then add phenanthroline to synthesize the desired
warhead (3) PaIVY complex.
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Chapter Six
Conclusion and Future Work
P. aeruginosa is a common threat to patients suffering from cystic fibrosis. These
patients typically have a reduced lifespan and often die from respiratory failure caused by
chronic bacterial lung infection with P. aeruginosa being a common contributor. It is
often difficult to fight off a P. aeruginosa infection due to its antibiotic resistant biofilm
production which may also be exacerbated by the secretion of a periplasmic protein,
Inhibitor of Vertebrate Lysozyme, named after its inhibition of lysozyme PaIVY In order
to inhibit the inhibitor a reactive warhead was designed and tested to see if mutating
specific residues or adding the reactive warhead would ultimately allow lysozyme to
effectively degrade the bacterium. Unfortunately based upon the data collected, mutating
specific residues and the addition of the reactive warhead (3) did not have an effect on the
inhibition PaIVY exhibits towards lysozyme suggesting that current models for how IVY
inhibit lysozymes7 may need to be reexamined.
Due to the potential impact inhibiting PaIVY could have, it has been worked on
by multiple individuals. A previous graduate student designed the protein purification
process that served as a basis for protein purification during this project, however
modifications were made to increase efficiency in this new work. This protocol consists
of an immobilized metal affinity chromatography nickel column His1, followed by a
dialysis with TEV cleavage to remove the His tag. Next the protein is run over the nickel
column a second time to separate the His tag from the protein. Subsequently the collected
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fraction is concentrated and run over a size exclusion chromatography column to ensure
purity of the correct protein. The only modification frequently used to his protocol was
the use of a different buffer during the SEC to eliminate the need for a buffer exchange
later. This modification is important because it allows for less time between protein
purification and having the final concentrated protein available for experiments. This is
especially important when reacting the protein with the any of the warheads as eventually
proteins degrade so the less time spent concentrating the more time there is for
experiments to be conducted with less of a chance of protein degradation. Primers were
designed to mutate the histidine 62 residue of PaIVY to alanine, and PCR was completed
for further investigation of this residue. This made it possible to observe the importance
of the H62 residue of PaIVY in the inhibition of lysozyme using a muramidase assay as
well as the importance of this residue when a reactive warhead is reacted with PaIVY.
The initial warhead designed was [Re(CO)3(H2O)3]Br+ (1), which was easily
water soluble. This compound did bind to PaIVY, but due to the formation of oligomers
its binding location was unable to be successfully seen on an HSQC NMR spectrum.
From here the warhead was redesigned to contain 1,10-phenanthroline (2-4) to block
PaIVY from forming these oligomeric complexes with the warhead. Both
[Re(CO)3(Phen)H2O]Br+ (2) and Re(CO)3(Phen)Cl+ (4) were poorly water soluble
making it difficult to get an HSQC NMR spectrum or do any further experiments. In
order to combat this obstacle, the easily water soluble [Re(CO)3(H2O)3]Br+ (1) was
reacted with PaIVY and then 1,10-phenanthroline was added. In order to ensure only the
monomer PaIVY in complex with the reactive warhead (3) was used for further
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experiments a size exclusion chromatography column was utilized. This became the
primary technique to form the reactive warhead (3) in complex with PaIVY.
Once the design of the reactive warhead and optimization of the complex
formation was achieved for the warhead (3), it became evident that this warhead was not
binding to the proposed active site, H62. This was seen on the wild type 15N PaIVY
HSQC NMR spectrum that when the protein was in complex with the warhead (3),
majority of the residues that experienced chemical shift perturbation were located near
H20. This was also confirmed on the H62A mutant 15N PaIVY HSQC NMR spectrum
that there were still chemical shifts once the H62 residue was no longer available for
binding. From this point site-directed mutagenesis was performed a second time to
mutate the histidine 20 residue to aspartic acid. The H20D mutant NMR spectra indicated
that H20 was experiencing little chemical shift perturbation but rather linebroadening
when reacted with the warhead warhead (3). This was clearly noticed in residues G38 and
S39 which were also residues that experienced chemical shift perturbation in the wild
type PaIVY spectrum as well as the H62A mutant spectrum. This data indicated that H20
alone was not the binding site for the warhead (3). It was proposed that perhaps a
conformational change was occurring when binding occurs. The H20D/H62A double
mutant NMR spectra confirms the theory that a conformational change is likely occurring
because in this spectrum there is no chemical shift perturbation. It was also noted from
this spectrum that some free protein did not react with the warhead (3). This is seen by
peak splitting on the spectrum as well as on both wild type and mutant 15N PaIVY HSQC
spectra.
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Once it was identified where warhead (3) was likely binding, muramidase assays
were performed for both wild type and all mutant PaIVYs with and without the addition
of the warhead (3) in order to identify if these specific residues or the addition of this
warhead had an effect on the inhibition of lysozyme. It was expected that wild type
PaIVY in the presence of lysozyme, specifically HEWL, would cause the fluorescent
signal to decrease at higher concentrations of PaIVY because the cells were not being
lysed. The muramidase assay confirmed this trend. However, the same trend was seen for
all mutant IVYs including H62A. This indicated that H62 may not be the only important
residue in the inhibition of lysozyme and that the residues neighboring H62 on the
exposed loop may also play a more important role in the inhibition than was previously
suggested by the crystal structure of IVY bound to HEWL.7 The muramidase assays with
the reactive warhead (3) also followed the same trend in which the fluorescence
decreased at higher concentrations of PaIVY for all mutants and wild type indicating that
warhead (3) was not binding to the correct site to block inhibition of lysozyme. However,
it is possible that there is still too much free protein that is unreacted with the warhead (3)
that was able to inhibit lysozyme. This hypothesis is supported by the fact that there were
split peaks on the NMR spectra that showed not all of the protein was in complex with
PaIVY, wild type or mutant. From this information it is difficult to conclude whether or
not warhead (3) really has an effect on the inhibition of PaIVY there is no way to
separate the free protein from the reacted protein. Resolving this ambiguity is important
for future studies of this system.
In the future there is still work that could be done to further understand where this
warhead (3) is binding as well as how the inhibition of lysozyme if affected when the
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warhead (3) is reacted with PaIVY. As suggested previously H62 may not be the only
important residue in the inhibition of lysozyme. In order to fully understand the inhibition
PaIVY exhibits towards lysozyme the residues neighboring His62, proline and aspartic
acid, should be mutated individually as well in conjunction with each other. This would
help indicate if all are responsible for the inhibition of lysozyme together. From here the
previously done experiments should be repeated with these mutants to get a better
understanding of the interaction with lysozyme as well as the effect the warhead (3)
might have when these residues are mutated.
Other mass spectrometry techniques would also be useful in identifying where the
warhead (3) is binding precisely to PaIVY such as a hydrogen-deuterium exchange mass
spectrometry (HDX-MS) experiment in conjunction with tandem mass spectrometry
(MS-MS) experiment. In an HDX-MS experiment the binding site and interaction is
revealed by monitoring the exchange rates between hydrogen and deuterium of the amide
proton of the protein. Hydrogen atoms not involved in the protein-warhead interaction
will exchange at a much more rapid pace than those involved in the interaction thus
indicate where binding is occurring.22 These experiments should be done in order to
provide valuable information indicating where the warhead (3) is binding and what
residues are involved which has yet to be obtained concretely from the research thus far.
Doing these experiments with the H62A, H20D, and H20D/H62A double mutant would
verify that this warhead has some promiscuity when binding between the H20 and H62
residues which can be addressed by experiments outlined further below.
Additionally, it would be beneficial to do fluorescence polarization studies on
PaIVY in complex with the warhead (3). Fluorescence anisotropy/polarization is a widely
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used technique in which polarized light is sent through a sample and the degree to which
the light is polarized is inversely proportional to the rate of molecular motion. A small
ligand will have rapid free rotation and therefore emit largely depolarized light while a
much larger molecule will have a limited rotation and therefore emit largely polarized
light.23 When the light reaches the detector the degree of polarization can indicate if a
ligand, or in this case the warhead (3) is bound and what percentage is bound to the
protein. This technique has many advantages such as not requiring any separation of
bound and free ligand, being nonradioactive, carrying out in solution phase, and
requiring relatively low volumes of sample making it an ideal technique to be used in
order to determine what percentage of protein is bound to the warhead (3).23 This
experiment should be done because it would indicate what percent of the warhead is
bound to PaIVY. One of the issues discussed previously is that after collecting the
monomer peak from the SEC of warhead (3) reacted PaIVY is that it is unknown how
much free protein is still in solution left to react and inhibit lysozyme. Knowing how
much free protein is left would give a good indication of how reactive this warhead (3)
truly is in an aqueous environment.
Furthermore, some of the previous work done with PaIVY by Aaron Schultz was
finding various drug fragments that bind to PaIVY. It would be beneficial to be able to
link these fragments with the warhead (3). Using the warhead (3) design outlined here, in
the future variations of phenanthroline or bipyridine complexes, such as dihydroxy
phenanthroline, can be used to help link previously identified drug fragments to the
reactive warhead (3) as well as help increase the solubility of the molecule, which was
one of the challenges in this project. Linking the warhead to previously identified drug
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fragments would increase the rate of the reaction by increasing the binding affinity and
specificity for the drug molecule towards PaIVY. There are many histidine containing
molecules found in the cellular environment. By linking these fragments, the warhead
will have a high specificity and be directed towards the target His62 residue rather than
H20 or any other histidine containing molecules. It would be beneficial to choose a
strong binding drug fragments near the H62 residue to link to the warhead in order to
increase the likelihood that the warhead would bind to the H62 residue instead of the H20
residue and therefore result in an irreversible inhibition of PaIVY. Linking the warhead to
different drug fragments or multiple would give a better understanding of binding and the
required residues for inhibition of lysozyme by PaIVY.
Lastly to expand on this research even further, an artificial sputum closely
resembling that of the sputum found in the lung environment of Cystic Fibrosis patients
should be used to understand how this warhead (3) would behave in a more realistic
environment. The artificial septum would contain many other cellular components found
in the lung environment that may have histidine residues. By using a realistic
environment, it would prove that once a full drug-molecule is created by linking the drug
fragments and the warhead (3) that there is high specificity of the complex towards His62
of PaIVY. Using this medium would also give a better understanding of how the
warhead complex would behave in an imperfect environment rather than a filtered
aqueous buffer that was used in the research done thus far.
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Appendix One

Figure A1.1. IR [Re(CO)3(H2O)3]Br+ (1)

Figure A1.2. 1H NMR [Re(CO)3(H2O)3]Br+ (1)
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Figure A1.3. 13C NMR [Re(CO)3(H2O)3]Br+ (1)

Figure A1.4. IR [Re(CO)3(Phen)H2O]Br+ (2)
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Figure A1.5. a.) 1H NMR [Re(CO)3(Phen)H2O]Br+ (2) full spectra b.) Zoomed in
downfield. C.) Zoomed in downfield

a.
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b.

Figure A1.6. a.) 13C NMR [Re(CO)3(Phen)H2O]Br+ (2) full spectra b.) Zoomed in
upfield
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Figure A1.7. IR [Re(CO)3(Phen)]Cl+ (4)
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Figure A1.8. 1H NMR [Re(CO)3(Phen)]Cl+ (4)
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Appendix Two
PaIVY Protocols
Aaron Schultz

Vectorless Host: E. coli BL21DE3PlysS
Plasmid: Pa3902 in PSpeedET vector
Promoter: Pbad-Forward
Antibiotic resistance: Kanamycin
Induction: 0.1% (w/v) L-(+)-Arabinose @ OD600 0.4-0.6
Extinction Coefficient: 31065
Molecular Weight: 14.5 kDa
pI: 5.69
Buffer Conditions: 40 mM KPhos, 200 mM KCl pH 8.0
Room temp stable
Withstands freeze-thaw cycles
Withstands de-salting into water
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Transformation

Materials:

Bucket with ice
SOC media
Plasmid
BL21DE3PLysS single shot cells
2 kanamycin LB/Agar plates
1 ampicillin LB/agar plate

Method

1. Place BL21DE3PLysS single shot cells ampule and plasmid in ice bucket to thaw
2. Place SOC media on benchtop from refrigerator to warm up
3. Place all three LB/Agar plates in incubator at 37oC
4. Once cells and plasmid are thawed, pipet 80 ng plasmid directly into cells and
put cells back on ice for 30 minutes.
5. Heat-shock for 42 seconds at 42oC
6. Place back on ice to rest for 5 minutes
7. Add 0.95mL SOC media to cells. Place in 37oC shaker @ 260 rpm for 1 hour
8. Pipet 100 µL and 200 µL cells onto kanamycin plate and 200 µl onto ampicillin
plate, spread onto plate evenly
9. Incubate at 37o overnight
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10. Parafilm and store in refrigerator. Shelf life ~ 2 weeks
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Small Inoculum
Materials
Two (2) 250 mL Erlenmeyer flasks (autoclaved) with 100 mL sterile LB or M9 in each
flask
Kanamycin stock
Transformation plate
Bunsen burner
Wire loop
Method
1. Pull transformation plates and set up loop assembly and Bunsen burner
2. Sterilize loop until red hot, allow to cool.
3. Loop 2-3 isolated colonies and stir into flask. Repeat for second flask
4. Add 100 µL kanamycin stock to each flask.
5. Cover top of flask with foil and place in shaker at 37oC overnight
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Large Inoculum
Materials
Two (2) autoclaved 2600 mL fernbach flasks with 1000mL sterile LB or M9 media
2000 mL flask with 500 mL media may be used as a substitute.
Flasks from small inoculum
Spectrophotometer
Plastic cuvettes
Four (4) 0.5 g Arabinose single shots
Kanamycin stock solution
Method
1. Turn on spectrophotometer
2. Spike 1000 mL media with 1000µL kanamycin stock solution if applicable
3. Reserve 1 mL of media as a blank.
4. Pull small inoculum from the shaker, pour contents into fernbach flasks.
Cover and shake to homogenize
5. Pipet 1 mL into cuvette, record OD600. Induction OD600=0.4-0.6 mAU
a. If OD600 is below 0.4, shake at 37oC for 20-minute intervals, taking
OD600 readings at each interval until absorbance is 0.4-0.6.
b. If OD600 is within range, move to step 6.
6. Reserve 4-6 mL non-induced mixture and place in 15 mL falcon tube
7. Induce with L-(+)-arabinose to 0.1%(w/v)
0.1% (w/v) is 1 g arabinose per 1000 mL media
8. Label flask and tape 15 mL non-induced control mixture to the fernbach flask
9. Place in shaker at 37oC overnight
Large Inoculum Centrifuge Protocol
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Materials
Sorvall RC6 plus super centrifuge
F10-6X500Y Rotor from cold room
500 mL centrifuge bottles with screw caps (6 for 2 L prep)
Cultures from large inoculum
Method
1. Turn on centrifuge and place rotor inside unit, screwing lid onto rotor, then
securing top screw into centrifuge.
2. Quick-temp the centrifuge by setting rotor on screen. Start spin then immediately
stop. This kickstarts the compressor.
3. Set parameters to 8000 RPM at 15 minutes, 4oC
4. Gather two 1 mL samples, induced and uninduced control, in eppendorf tubes
5. Pour large inoculum culture into centrifuge bottles. Volume should be around 2/3
height of bottle.
6. Balance filled bottles against each other using Harvard balance.
7. Place balanced bottles across from one another to balance rotor
8. Secure lid to rotor
9. Secure rotor to centrifuge
10. Confirm rotor and spin settings
11. Start and step back
WARNING! ROTOR IS SUSCEPTIBLE TO FAILURE DURING
ACCELERATION AND DECELERATION
12. Pour off clear supernatant and store pellets in -20oC freezer
13. Bleach supernatant and culture bottles for 20 minutes
14. Bleach work area and balance
Buffers
Materials
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1 L or 2 L graduated cylinder
2.5 L beaker with stir bar
Dibasic potassium phosphate
Monobasic potassium phosphate
Potassium chloride
Imidazole
Hydrochloric acid
Potassium hydroxide
Digital analytical balance
Stir plate
pH meter
Vacuum filter apparatus with appropriate filter paper
Methods
1. Place ~500 mL 18 MΩ deionized water in beaker with stir bar. Place beaker on
stir plate
2. Weigh ingredients using analytical balance
3. Dissolve ingredients into water
4. Adjust pH to 8.0 using pH meter and appropriate acid or base
5. Pour into appropriate graduated cylinder and bring up to volume using 18 MΩ DI
H2 O
6. Vacuum filter and degas buffer.
7. Store Buffer A, Buffer B, and SEC buffer in clean 1L glass screw cap bottle
8. Dialysis buffer may be stored in a 2.5 L Nalgene beaker covered with plastic wrap
9. Apply appropriate label with name, date, product name, contents and pH.
Example: AS 7/1/19 PaIVY Buffer A 40 mM KPhos 200 mM KCl, 20 mM imidazole
pH 8
10. Store in deli-style refrigerator
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Buffer Contents
Running

Elution

SEC

Dialysis

Buffer

Buffer

Buffer

Buffer

“Buffer A”

“Buffer B”

Volume

1 Liter

1 Liter

1 Liter

2 Liters

pH

8.0

8.0

8.0

8.0

Dibasic Potassium Phosphate

20 mM

20 mM

20 mM

20 mM

K2HPO4 (Anhydrous)

3.846 g

3.846 g

3.846 g

6.972 g

Monobasic Potassium Phosphate

20 mM

20 mM

20 mM

20 mM

KH2PO4 (Anhydrous)

2.722 g

2.722 g

2.722 g

5.444 g

Potassium Chloride

200 mM

200 mM

200 mM

200 mM

KCl

14.910 g

14.910 g

14.910 g

29.820 g

Imidazole

20 mM

400 mM

Do not

Do not

1.362 g

27.232 g

add

add

Buffer Name
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Homogenization
Materials
500 mL centrifuge bottles with pellets from large inoculum centrifugation
20 mL buffer A
60 mL homogenizer with plastic plunger
Ice bucket with ice
Method
1. Pour 20 mL buffer A into one centrifuge bottle with pellet. Vortex until pellet has
completely loosened into the buffer.
2. Pour off contents of bottle into next centrifuge bottle with pellet.
3. Repeat steps 1-2 until all pellets have been loosened
4. Pour contents into homogenizer and place in ice
5. Use plunger with an up/down and twisting motion to homogenize cells into buffer
A. Product should be a uniform, creamy, light tan solution
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French Press
CAUTION! VERY DANGEROUS. USES A COMBINATION OF HIGH
PRESSURE FROM AN OPEN HYDRAULIC PRESS AND 10 kg STEEL
CELL. SEVERE INJURY MAY OCCUR WITH IMPROPER USE.
Materials
open hydraulic french press
french press cell with T-bar plunger
homogenized cell culture
500 mL beaker with ice
Bucket with ice
Method
1. Ensure new french press machine is set to “down” and “pause”. Turn on machine
2. Lubricate rubber on plunger with petroleum jelly and assemble cell body with Tbar plunger to “MAX FILL” line
3. Place upside down onto cell stand
4. Assemble base of cell with outlet nozzle and flow restrictor screw tightened
5. Pour homogenized sample into cell body. Make sure to leave about 3 cm of room
for the cell base.
6. Place cell base onto cell body and invert to right side up.
7. Place assembled cell into press with the T-bar above the T bar plunger notches.
Cell should be positioned with the plastic button on the cell body in line with the
steel screw rod, outlet nozzle facing forward, and flow restrictor screw easily
accessed to the left.
8. Secure cell in place using steel cross bar with screw assembly.
9. Attach outlet nozzle hose
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10. Set to “LOW” and “RUN”. Allow pressure to stabilize (~1750 PSI). Make sure
cell has not moved from its restraints and that the T-bar has made flush contact
with the top plate. You should not see any flow through the outlet hose.
11. Set to “HIGH”. Allow pressure to stabilize. You should not see flow through the
outlet hose.
12. Using the small mallet, tap the flow restrictor screw in a counter-clockwise
fashion until a slow flow is seen in the outlet hose.
13. Once flow has reached the end of the outlet hose, regulate the flow to 1-2 drops
per second into a small centrifuge bottle. Contents in the hose should look like a
dark tan liquid with cream liquid on top.
14. Run until the plunger reaches “STOP”. Set machine to “PAUSE”
15. Set machine to “DOWN” and “RUN”.
16. Repeat steps 3-15 two times.
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Crude Lysate Centrifugation
Materials
Sorvall RC6 plus super centrifuge
F21S 8X50Y centrifuge rotor from cold room
Crude lysate from french press
Two (2) 30 mL centrifuge bottles
Method
1. Turn on centrifuge
2. Input run conditions 18000 RPM, 45 Min, 4oC
3. Install rotor fastening lid first by tightening bottom screw, then top screw
4. Select rotor
5. Quick start compressor by starting and immediately stopping run
6. Balance samples using Harvard balance
7. Place samples in centrifuge directly across from one another (i.e. slots 1 and 5)
8. Fasten bottom screw and top screw to rotor
9. Confirm run conditions and rotor selection
10. Start and step back.
WARNING! ROTOR IS SUSCEPTIBLE TO FAILURE DURING
ACCELERATION AND DECELERATION
11. After run is complete immediately pour off supernatant into a 50 mL falcon tube.
12. Take a 100µL sample of the supernatant placing it in a 1.5mL epi tube. Label
CRUDE
13. Inspect pellet. The outside edge of the pellet should be glassy and transparent.
This represents cell membrane fragments. As you inspect closer to the center, the
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color should be tan with a dark bullseye representing heavier bacterial cell
fragments.
CromLab Program Basics for NGC Liquid Chromatography System

1. System pump buffer selection icon for pump A and pump B
a. Allows to change between buffers using valve
2. System pump operation icon
a. Allows pump A and B operation. Isocratic or gradient.
3. Sample pump operation icon
a. load and/or inject sample
4. Sample pump flow selection icon
a. Changes selection to loop or direct column inject for sample pump and
system pump
5. Column selection icon
a. changes flow to selected column
6. Column
7. UV/Connectivity icon
a. toggle lamps on/off, zero absorbance readings
8. Fraction collection icon
a. set collection tube parameters- type/volume/amount
9. Waste icon
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1st Ni-column (His-1) Purification by Immobilized Metal Affinity Chromatography
(IMAC)
The purpose of this purification step is to separate our protein from the rest of the
bacterial proteins by leveraging the utility of the 6 histidine tag. When the crude lysate
flows across the nickel column, the nickel binds PaIVY which contains a his tag. Low
imidazole concentration running buffer that flows over the column in the next step helps
kick off weakly binding proteins. High concentration imidazole in an elution buffer
knocks PaIVY off of the nickel column. There are a few important cautionary steps
whenever purifying protein on the NGC. First, make sure you do not introduce any air
into the system.Introducing air into a column can dry out the column matrix and destroy
the column. Second, make sure flow is within operating range for the column you are
using. Using a flow rate too high for a column will compress the matrix and destroy the
column. Third, ensure that the fraction collector is turned on and is connected to the NGC
before loading your protein. If the fraction collector is not communicating with the NGC,
the entire system must be restarted. Finally, once the protein is loaded, do not zero out the
absorbance. This will skew your results.
Materials
NGC liquid chromatography system running ChromLab program
PaIVY buffer A (see page 8) placed in buffer selector 3A
PaIVY buffer B (see page 8) placed in buffer selector 3B
Centrifuged crude lysate
three (3) 50 mL falcon tubes labelled 1) buffer A 2) flow through 3) peak fractions
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Methods
1. Equilibrate the Ni-column.
a. Set column selection icon to slot 1
b. Run DI water (system pump buffer selector slot 2) at 5 mL/min for 25 mL
c. Run buffer B (system pump buffer selector slot 3 100%B) @ 5mL/min 25
mL
d. Run buffer A (system pump buffer selector slot 3 0%B) @5mL/min 25
mL, zeroing out the absorbance under UV/Conn icon within 5 mL of
completion
e. set column selection icon to bypass
f. set sample pump flow selection to “Sample pump direct inject, system
pump waste.” line on computer diagram should be light blue from the
sample pump through the column and into waste.
g. using sample pump, direct inject 10 mL buffer A to clear out sample
pump.
h. turn column selection icon back to position 1
i. clear out run.
2. Load the crude lysate
a. take the empty 50 mL falcon tube labelled “flow through” and place in
plastic waste jug with lines in the falcon. The tube should not fall through
into the bottom. it should sit on the lid of the waste collector.
b. determine volume of centrifuged lysate and set injection volume of sample
pump.
c. place falcon tube into clamp by sample pump. Insert brown sample
loading tube to the bottom of the falcon.
d. load sample using sample pump at 5 mL/min. stop pump just before all
sample is gone. you should see a large plateau on the chromatogram.
e. add approximately 10 mL buffer A at 5 mL/min to residual crude lysate
and run sample pump for <10 mL to ensure injection of all crude lysate.
f. remove “flow through” falcon tube from the waste container

87

g. switch sample pump flow selection to “Manual inject loop, system pump
to column.” Flow line on computer diagram should show a red injection
loop and a green line running from the system pump through the column
and to waste.
3. Set up fraction collection
a. ensure fraction collector is on, has clean racks in it, and is connected to the
system.
b. click on the blue fraction collector viewer icon and press both “remove
empty racks” and “remove all”
c. close out window
d. double click on fraction collector to open window. Rack type should be
F1 (12-13 mm X 100mm tubes) Start collection from A1 and end at B90.
Fraction size should be 4 mL.
4. Achieve adequate separation.
a. Set system pump to 5 mL/min, 0% B, for 25 mL. Start pump
b. turn on fraction collection by double clicking fraction collector and
pressing “collect.” you are now collecting fractions.
c. absorbance line should be near or at baseline after 25 mL run. if not, run
10 mL at a time until the baseline of A280 is less than 50 mAU
5. Elute PaIVY from the column.
a. Under the system pump, choose gradient, initial %B 0%, final %B 100%,
25 mL then click the check box to run final B% for an additional 15 mL.
b. Start flow. you should start to see a peak around 30%B
c. at 100%B, you will notice that A280 flattens out around 300 mAU. To
establish this is absorbance from the high concentration imidazole, run 15
mL 0%B and watch the absorbance line and the connectivity line. the line
shapes should be very similar. A280 should drop down close to zero.

6. Finishing up
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a. Stop collection
b. press “reset arm”
c. collect fractions from peak in 50 mL falcon labelled “peak fraction”
d. add 1:1000 EDTA to peak fraction falcon.
i.

if you collected 16 mL sample, add 16µL EDTA

e. save run under style PaIVY_(media used)_(labelling if
applicable)_His1_Yearmonthday_(last name)
i.

PaIVY_M9_15N_His1_20190708_Schultz

ii.

PaIVY_LB_His1_20190708_Schultz

f. close out run and open up analysis
g. deselect every line trace except A280, %B, and connectivity
h. Create run report under File
i. save in a folder created on desktop.

89

Dialysis and TEV cleavage
The purpose of this step is to remove excess imidazole from the peak fractions to allow
cleavage of the TEV cleavage site ENLYFQG to separate the 6-his tag from PaIVY
Materials
Pooled peak fractions containing 0.5 mM (1:1000 dilution) Disodium EDTA from 0.5 M
stock
TEV
3500 MW Snakeskin® dialysis tubing with green tube clamps
2L dialysis buffer (see page 8)
Methods
1. Soak a strip of 3500 MW Snakeskin® dialysis tubing in dialysis buffer to hydrate
dialysis membrane
2. Fold the first end of the dialysis tubing in a “greek key” motif by making one
large fold, then folding the large fold in half. clamp the folded membrane with a
green clip.
3. Using a disposable pipet, transfer the pooled fraction containing EDTA into the
dialysis tubing. Clamp the second end of the tubing using the same folding
technique. make sure there is an air bubble in the dialysis tubing, allowing the
tubing to float in the dialysis buffer.
4. Place dialysis tubing in dialysis buffer for at least 3 hours to reduce the imidazole
concentration in the pooled fractions.
5. After dialysis, transfer the dialyzed protein into a clean 50 mL falcon tube.
6. add TEV at a ratio of 1 part TEV to 50 parts protein. (eg. if you have 50 mg
PaIVY, add 1 mg of TEV)
7. set on benchtop overnight
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2nd Ni-column (His-2) Purification by Immobilized Metal Affinity Chromatography
(IMAC)
The purpose of this purification step is to further purify your protein by separating the
cleaved PaIVY protein from the TEV, N-terminal his-tag, and any non-specific binding
proteins that co-eluted with PaIVY during the first nickel column. We use a cleave and
clear strategy to remove the his tag from our protein. By running our protein over a nickel
column a second time, the flow through will contain PaIVY and the His tag along with
TEV will come off of the column with the elution fraction.
Materials
NGC liquid chromatography system running ChromLab program
PaIVY buffer A (see page 8) placed in buffer selector 3A
PaIVY buffer B (see page 8) placed in buffer selector 3B
Dialyzed PaIVY with TEV
Two (2) 50 mL falcon tubes labelled 1) buffer A 2) His 2 Peak Fraction
Methods
1. Equilibrate the Ni-column.
j. a.Set column selection icon to slot 1
k. Run DI water (system pump buffer selector slot 2) at 5 mL/min for 25 mL
l. Run buffer B (system pump buffer selector slot 3 100%B) @ 5mL/min 25
mL
m. Run buffer A (system pump buffer selector slot 3 0%B) @5mL/min 25
mL, zeroing out the absorbance under UV/Conn icon within 5 mL of
completion
n. set column selection icon to bypass
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o. set sample pump flow selection to “Sample pump direct inject, system
pump waste.” line on computer diagram should be light blue from the
sample pump through the column and into waste.
p. using sample pump, direct inject 10 mL buffer A to clear out sample
pump.
q. turn column selection icon back to position 1
r. clear out run.
7. Load the PaIVY and TEV sample
a. take the empty 50 mL falcon tube labelled “His 2 Peak Fraction” and
place in plastic waste jug with lines in the falcon. The tube should not fall
through into the bottom. it should sit on the lid of the waste collector.
b. determine volume and set injection volume of sample pump.
c. place falcon tube into clamp by sample pump. Insert brown sample
loading tube to the bottom of the falcon.
d. load sample using sample pump at 5 mL/min. stop pump just before all
sample is gone. you should see a large plateau on the chromatogram.
e. add approximately 10 mL buffer A at 5 mL/min to residual protein and
run sample pump for <10 mL to ensure injection of all protein.
f. remove “His 2 peak fraction” falcon tube from the waste container. this is
where your protein is.
g. switch sample pump flow selection to “Manual inject loop, system pump
to column.” Flow line on computer diagram should show a red injection
loop and a green line running from the system pump through the column
and to waste.
8. Set up fraction collection
a. ensure fraction collector is on, has clean racks in it, and is connected to the
system.
b. click on the blue fraction collector viewer icon and press both “remove
empty racks” and “remove all”
c. close out window
d. double click on fraction collector to open window. Rack type should be
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F1 (12-13 mm X 100mm tubes) Start collection from A1 and end at B90.
Fraction size should be 4 mL.

9. Achieve adequate separation.
a. Set system pump to 5 mL/min, 0% B, for 25 mL. Start pump
b. turn on fraction collection by double clicking fraction collector and
pressing “collect.” you are now collecting fractions.
c. absorbance line should be near or at baseline after 25 mL run. if not, run
10 mL at a time until the baseline of A280 is less than 100 mAU
10. Elute His tag and TEV from the column.
a. Under the system pump, choose gradient, initial %B 0%, final %B 100%,
25 mL then click the check box to run final B% for an additional 15 mL.
b. Start flow. you should start to see a peak around 30%B
c. at 100%B, you will notice that A280 flattens out around 300 mAU. To
establish this is absorbance from the high concentration imidazole, run 15
mL 0%B and watch the absorbance line and the connectivity line. the line
shapes should be very similar. A280 should drop down close to zero.
11. Finishing up
a. Stop collection
b. press “reset arm”
c. save run under style PaIVY_(media used)_(labelling if
applicable)_His1_Yearmonthday_(last name)
i.

PaIVY_M9_15N_His2_20190708_Schultz

ii.

PaIVY_LB_His2_20190708_Schultz

d. close out run and open up analysis
e. deselect every line trace except A280, %B, and connectivity
f. Create run report under File
g. save in a folder created on desktop.
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Size Exclusion Chromatography (SEC) purification
The purpose of this step is to ensure that the protein collected from the previous
purification steps is pure, and is the molecular weight expected for PaIVY. This column
is much more fragile than the IMAC columns. Maximum flow through these columns is
0.5-0.7 mL/min. minimum volume required to equilibrate column is 120 mL so plan
accordingly. If the column is stored in ethanol, it will require 120 mL of water, then 120
mL of SEC buffer to equilibrate, taking about 6-8 hours.
Materials
NGC liquid chromatography system running ChromLab program
PaIVY SEC buffer (see page 8) placed in buffer selector 6
His-2 purified peak fraction concentrated to under 5 mL.
one (1) 50 mL falcon tube labeled SEC purified PaIVY
Methods
1. Ensure SEC column (column selector 5) is equilibrated to PaIVY SEC buffer
(buffer selector 6) and baseline is zeroed.
2. direct inject the His-2 purified, concentrated PaIVY onto the SEC column at 0.5
mL/min
3. Change the sample pump flow selector to “system pump to column, sample pump
direct inject”
4. Set system pump for 0%B 120 mL at 0.5 mL/min and start the pump.
5. Immediately start fraction collection (4 mL)
6. PaIVY will come off the column around 80 mL.
7. Pool the peak fractions into the 50 mL falcon tube labeled SEC purified PaIVY
and store in deli-style refrigerator.
8. Save run.
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